News - MET exon 14 mutation

Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry. (PubMed, JTO Clin Res Rep)

The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.

1 day ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion

Oncomine™ Dx Target Test

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study. (PubMed, Lancet Reg Health West Pac)

Savolitinib demonstrated robust and durable efficacy in patients with METex14-mutated, locally advanced NSCLC with manageable safety, supporting savolitinib as a treatment option in this disease setting. HUTCHMED, AstraZeneca.

1 day ago

P3 data • Journal

MET (MET proto-oncogene, receptor tyrosine kinase)

MET exon 14 mutation • MET mutation

Orpathys (savolitinib)

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer. (PubMed, Lung Cancer Manag)

The incremental cost-effectiveness ratio (ICER) of Capmatinib treatment vs. Tepotinib treatment was calculated at 60,977.28 USD/QALY. Tepotinib was not cost-effective compared to Capmatinib as the second-line treatment for advanced or metastatic NSCLC patients with MET exon 14 skipping mutations in China.

3 days ago

Review • Journal • HEOR • Cost-effectiveness

MET (MET proto-oncogene, receptor tyrosine kinase)

MET exon 14 mutation • MET mutation

Tepmetko (tepotinib) • Tabrecta (capmatinib)

DO2.22.01: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)

P1, N=55, Recruiting, DeuterOncology | N=25 --> 55 | Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Sep 2027 | Active, not recruiting --> Recruiting

4 days ago

Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • First-in-human

MET (MET proto-oncogene, receptor tyrosine kinase)

MET exon 14 mutation

DO-2

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P2, N=38, Recruiting, Shanghai Henlius Biotech | N=22 --> 38

9 days ago

Enrollment change

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • EGFR mutation • MET exon 14 mutation

HLX43

11d

Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens. (PubMed, Cancer Cytopathol)

These findings demonstrate distinct TMB and PD-L1 profiles that may identify patients who will benefit from ICI therapy. Cytology specimens provide adequate material for biomarker testing, which underscores their value in guiding immunotherapy decisions.

11 days ago

Retrospective data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase)

PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • ALK rearrangement • MET exon 14 mutation

13d

HLX43-NSCLC201: Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study (2025-523803-31-00)

P1/2, N=22, Not yet recruiting, Shanghai Henlius Biotech Inc.

13 days ago

New P1/2 trial

PD-L1 expression • EGFR mutation • MET exon 14 mutation

HLX43

13d

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)

P1, N=40, Active, not recruiting, Avistone Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | N=264 --> 40

13 days ago

Enrollment closed • Enrollment change • First-in-human

MET (MET proto-oncogene, receptor tyrosine kinase)

MET amplification • MET exon 14 mutation • MET overexpression • MET mutation

14d

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (clinicaltrials.gov)

P3, N=605, Active, not recruiting, Daiichi Sankyo | Trial completion date: Jan 2026 --> Feb 2027

14 days ago

Trial completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation

docetaxel • Datroway (datopotamab deruxtecan-dlnk)

15d

LUNG-MAP Sub-Study: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (clinicaltrials.gov)

P2, N=124, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

15 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive

FoundationOne® CDx

Retevmo (selpercatinib)

17d

EAY131-C2: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (clinicaltrials.gov)

P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | N=35 --> 20 | Trial completion date: Feb 2026 --> Dec 2026

17 days ago

Enrollment change • Trial completion date

MET exon 14 mutation

Xalkori (crizotinib)

17d

TROPION-Lung17: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)

P3, N=400, Recruiting, AstraZeneca | N=103 --> 400

17 days ago

Enrollment change • Trial initiation date

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS G12C • MET exon 14 mutation • KRAS G12

docetaxel • Datroway (datopotamab deruxtecan-dlnk)